Trial · NCT01948830
Results by group292
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 292
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | 6.2 | Standard Error 0.70 | Letters (EDTRS) | |
| Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | 8.1 | Standard Error 0.70 | Letters (EDTRS) | |
| Number of Visits Scheduled | Group I Ranibizumab 0.5 mg TER | 8.9 | Standard Deviation 2.56 | Number of visits | |
| Number of Visits Scheduled | Group II Ranibizumab 0.5 mg Monthly | 11.2 | Standard Deviation 2.37 | Number of visits | |
| Change in BCVA From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | 6.4 | Standard Deviation 14.11 | Letters (EDTRS) | |
| Change in BCVA From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | 8.0 | Standard Deviation 11.61 | Letters (EDTRS) | |
| Average BCVA Change From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | 6.3 | Standard Deviation 10.50 | Letters (EDTRS) | |
| Average BCVA Change From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | 7.1 | Standard Deviation 9.41 | Letters (EDTRS) | |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | Month 1 (n=320, 322) | 4.6 | Standard Deviation 7.56 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | Month 1 (n=320, 322) | 4.2 | Standard Deviation 6.98 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | Month 2 (n=240, 316) | 5.5 | Standard Deviation 8.64 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | Month 2 (n=240, 316) | 5.8 | Standard Deviation 8.58 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | Month 3 (n=247, 311) | 6.7 | Standard Deviation 9.09 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | Month 3 (n=247, 311) | 6.7 | Standard Deviation 9.19 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | Month 4 (n=213, 314) | 7.0 | Standard Deviation 10.90 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | Month 4 (n=213, 314) | 7.3 | Standard Deviation 9.95 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | Month 5 (n=231, 302) | 6.0 | Standard Deviation 11.34 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | Month 5 (n=231, 302) | 7.7 | Standard Deviation 10.61 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group I Ranibizumab 0.5 mg TER | month 6 (n=205, 302) | 6.9 | Standard Deviation 13.34 | Letters (EDTRS) |
| Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 | Group II Ranibizumab 0.5 mg Monthly | month 6 (n=205, 302) | 7.9 | Standard Deviation 10.83 | Letters (EDTRS) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01948830/results